Etavopivat

Unknown / undisclosed

Filedsubmitted

Evidence outlook · regulatory review

Sickle Cell Disease: application submitted to FDA

Novo Nordisk submits the etavopivat NDA to the FDA (2026-11-13). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Latest reported trial: HIBISCUS (NCT04624659) · Phase 3 · met primary endpoint · grade pending

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Sickle Cell Disease
NCT06609226 · Novo Nordisk A/S
2025-01-10 – 2030-12-30 · Sickle Cell Disease, Thalassemia
What this study did
Phase 2 (5)
Sickle Cell Disease
NCT06198712 · Forma Therapeutics, Inc.
2023-01-12 – 2029-08-08 · Sickle Cell Disease
What this study did
NCT05725902 · Novo Nordisk A/S
2024-03-09 – 2026-03-09 · Sickle Cell Disease
What this study did
NCT04987489 · Forma Therapeutics, Inc.
2022-03-28 – 2025-09-24 · Sickle Cell Disease, Thalassemia
What this study did
Other / comorbidity
NCT05568225 · Forma Therapeutics, Inc.
2022-11-15 – 2024-07-15 · Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
What this study did
Phase 1 (5)
Sickle Cell Disease
NCT07023029 · Novo Nordisk A/S
2025-06-09 – 2025-09-22 · Healthy Volunteers, Sickle Cell Disease, Thalassemia
What this study did
NCT06813924 · Novo Nordisk A/S
2025-02-06 – 2025-05-27 · Healthy Volunteers Sickle Cell Disease, Thalassemia
What this study did
NCT06581627 · Novo Nordisk A/S
2024-08-26 – 2024-10-31 · Healthy Volunteers, Sickle Cell Disease, Thalassemia
What this study did
NCT06433661 · Novo Nordisk A/S
2024-05-28 – 2024-07-08 · Healthy Volunteers Sickle Cell Disease, Thalassemia
What this study did
Other / comorbidity
NCT06336018 · Novo Nordisk A/S
2024-05-20 – 2025-08-01 · Liver Diseases
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Sickle Cell Disease: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Etavopivat: this drugPhase 3—Pyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Crizanlizumab-Tmca (Adakveo)ApprovedMonoclonal antibodyP-selectinPartial signalFeatured results are non-efficacy only in this race
Exagamglogene Autotemcel (Casgevy)ApprovedGene therapy / editingBCL11A erythroid enhancer (gene editing)Weak signalNo reviewed efficacy summary in this indication
Hydroxyurea (Droxia)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Siklos)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Xromi)ApprovedSmall moleculeRibonucleotide reductaseWeak signalNo reviewed efficacy summary in this indication
L-Glutamine (Endari)ApprovedSmall moleculeAmino AcidReliable signal
NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15)
Lovotibeglogene Autotemcel (Lyfgenia)ApprovedGene therapy / editingBeta-globin gene addition (betaA-T87Q)not yet gradedNo reviewed efficacy summary in this indication
Mitapivat (Aqvesme)
Approved(overall)
Small moleculePyruvate kinase
Partial signal(overall)
No reviewed efficacy summary in this indication
Mitapivat (Pyrukynd)Phase 3Small moleculePyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Decitabine / Tetrahydrouridine (NDec)Phase 2Small moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
HBI-002Phase 2Small moleculeCarbon monoxide (CO)-based gas therapeutic; oral liquid CO formulationnot yet gradedNo reviewed efficacy summary in this indication
ITU512Phase 1/2Small moleculeWIZ transcription factornot yet gradedNo reviewed efficacy summary in this indication
Nula-CelPhase 1/2Gene or cell therapy (subtype unspecified)HBB gene (sickle mutation correction)not yet gradedNo reviewed efficacy summary in this indication
Ristoglogene AutogetemcelPhase 1/2Gene therapy / editingHBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
DISC-3405Phase 1Monoclonal antibodyTMPRSS6 (matriptase-2)not yet gradedNo reviewed efficacy summary in this indication
SCD-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
VAS-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Renizgamglogene AutogedtemcelDiscontinuedGene or cell therapy (subtype unspecified)HBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)Reliable signal
NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Etavopivat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
August 2027 (2)
Phase 2Sickle Cell DiseaseRecruiting
Est. primary completion 2027-08-20 · NCT05953584 · CT.gov ↗
What to watch
Phase 3Sickle Cell DiseaseRecruiting
Est. primary completion 2027-08-27 · NCT06612268 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 2Sickle Cell DiseaseRecruiting
Est. primary completion 2028-02-23 · NCT06198712 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 3Sickle Cell DiseaseRecruiting
Est. primary completion 2030-12-30 · NCT06609226 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 November 2026Filing submittedNovo Nordisk submits the etavopivat NDA to the FDA
US, FDA · Novo Nordisk · Source ↗
13 November 2026Filing submittedNovo Nordisk submits the etavopivat MAA to the EMA
EU, EMA · Novo Nordisk · Source ↗
20 April 2026Topline resultEtavopivat HIBISCUS phase 3 topline results
April 2026Topline resultHIBISCUS topline: fewer vaso-occlusive crises with etavopivat
Novo Nordisk · Source ↗